Madalena Esteves
Translator — Portuguese
Portugal
Articles translated into Portuguese by Madalena Esteves
- Interim update from Vico Therapeutics on their CAG-targeting drug, VO659
- Moving into the Fast Lane: uniQure and the FDA Are on the Same Track for Accelerated Approval
- Going boldly: First person treated in Phase 1 clinical trial by Alnylam Pharmaceuticals
- Self-determination on the HD journey: the role of Advanced Care Planning
- Giving Thanks to the Huntington's Disease Family Community for Advancing Research
- 2024 HDBuzz Prize: Beyond nerve cells – who are the other players in the HD brain?
- Face-to-face: Huntington’s disease families are heard by the FDA
- We are not alone, and are seeing more RED
- The dust has settled: Sage’s dalzanemdor won’t advance for cognitive impairment
- Huntington Study Group (HSG) Conference 2024 – Day 2
- Huntington Study Group (HSG) Conference 2024 – Day 3
- Huntington Study Group (HSG) Conference 2024 – Day 1
- 2024 HDBuzz Prize: Thinking beyond therapies - it’s time to consider racial disparity in HD care and research
- Announcing the 2024 HDBuzz Prize for Young Science Writers!
- 2024 HDBuzz Prize: Social Skills - The Hidden Gem in Improving Quality of Life for People with Huntington's disease?
- Interruptions are encouraged
- Bringing HD Treatments to Market: The Role of Regulatory Oversight
- Highlighting a link between brain disorders on Ataxia Awareness Day
- Hope vs. hype: seeking truth in recent Prilenia headlines
- Mini brains grown in a dish shed light on Huntington’s disease and how we might treat it
- Hereditary Disease Foundation (HDF) conference 2024 – Day 4
- Hereditary Disease Foundation (HDF) conference 2024 – Day 2
- Hereditary Disease Foundation (HDF) conference 2024 – Day 3
- Hereditary Disease Foundation (HDF) conference 2024 – Day 1
- Buckle in: Gene therapy AMT-130 appears to slow down signs of Huntington’s disease in Phase I/II clinical trial
- Blue skies for Skyhawk: Positive news from Phase 1 trial for SKY-0515
- Positive news from Wave Life Sciences SELECT-HD trial
- No pivot needed for PTC-518
- SURVEYOR opens the door for drugs that treat cognition
- The VIP section: velvet ropes for the brain and how to get in
- Two birds, one stone: HTT-lowering drugs also target CAG expansions
- Hats off to brain donors on Brain Donation Awareness Day
- A new era for HDBuzz
- A sprinkling of good news for the treatment of HD chorea
- How many is too many? Exploring the toxic CAG threshold in the Huntington’s disease brain
- Making babies: having a family, the HD way
- Cry your eyes out: detecting huntingtin in tears
- The director’s cut: how CAG repeats change the editing of genetic messages
- Huntington's Disease Therapeutics Conference 2024 - Day 3
- Understanding expansions at the single cell level
- Huntington's Disease Therapeutics Conference 2024 - Day 2
- Huntington's Disease Therapeutics Conference 2024 - Day 1
- CRISPR-based drugs: one giant leap for mankind
- Steady progress from uniQure - promising data to end the year
- Regulating repetition: Gaining control of CAG repeats could slow progression of Huntington’s disease
- Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD
- Could halting CAG expansions be a new treatment for HD?
- Tipping the balance; new insights into HD genetic modifiers
- Drug to treat movement symptoms of HD approved by FDA
- Youthful competitors: young brain cells oust the old
- Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
- Huntington’s disease therapeutics conference 2023 - Day 3
- Huntington’s disease therapeutics conference 2023 - Day 2
- Huntington’s disease therapeutics conference 2023 - Day 1
- PROOF-HD study of pridopidine ends with negative result
- Astrocytes: The new star in HD research?
- Hunting for balance: how the huntingtin protein compensates in HD
- Roche Phase II GENERATION HD2 study underway
- uniQure gets the green light to resume testing HD gene therapy
- A new roadmap to track Huntington’s disease progression
- Disappointing news from Novartis about branaplam and the VIBRANT-HD trial